Solid Dosage
GEA designs, produces and delivers innovative, integrated solutions for every stage of the manufacturing process of anti-diabetic drugs
With diabetes and the global anti-diabetes drug market on the rise, demand for GEA technologies for the production of these life-saving drugs is already high and set to increase, particularly in new markets and emerging economies
It is estimated that approximately 6.4% of the adult population worldwide has diabetes, leading to a huge demand for oral anti-diabetes drugs. To be able to cater for this demand, high-volume or mass production of these medicines is a fundamental requirement. It enables companies to produce goods faster and reduce the overall per unit production cost, allowing them to make anti-diabetes medications available to less-developed countries.
GEA has been instrumental in designing, producing and delivering innovative, integrated solutions for every stage of the manufacturing process: from materials handling to tablet coating, automation and monitoring. We continue to support this high-volume batch-based production with ongoing improvements and innovative developments.
One example is our range of double-sided tablet presses to accommodate the fact that many oral anti-diabetes medicines are bilayer combination drugs, consisting of two separate layers for each API.
Another trend that we have observed is the move towards continuous manufacturing (CM). Providing increased yields, lower utility consumption and reduced waste, CM meets the industry’s demands for improved production economics and increased manufacturing flexibility.
Focusing on quality during the whole product lifecycle and decreasing any associated risks, GEA is helping its customers to develop, evaluate and optimize continuous processing techniques to enable them to bring new products to market faster and cheaper.
Affichage de 4 sur 25
En tant qu’intégrateurs de systèmes, nous associons notre savoir faire en matière de technologie de process et d'engineering aux logiciels de contrôle commande et de supervision développés par des leaders du marché.
Contained Materials Handling solutions for Primary and Secondary Pharmaceuticals and Healthcare. With extensive experience within the generics sector, supply a wide range of technologies and equipment that improve and enhance the efficiency and performance of Oral Solid Dosage production.
The ConsiGma® DC for direct compression is the latest expansion of GEA's continuous portfolio for cost effective, compact, high yield manufacturing systems. It offers a robust and flexible manufacturing method for a wide range of products.
Continuous Processing is becoming more and more important in the pharmaceutical industry. GEA takes the lead in introducing this innovative technology with ConsiGma® - continuous high-shear granulation and drying lines.
Avec le GEA kytero 10, les chercheurs et les développeurs de l'industrie biopharmaceutique, de l'agroalimentaire et des nouveaux aliments disposent d'un accélérateur puissant de dernière génération.
Que diriez-vous si votre chocolat préféré n’avait pas besoin de fèves de cacao et si votre café était produit localement ? Alors que le dérèglement climatique, les hausses de prix et les préoccupations éthiques frappent de plein fouet deux de nos péchés mignons préférés, les chercheurs réimaginent la façon dont nous les produisons en abandonnant la monoculture pour miser sur les microbes. L’objectif est de préserver l’arôme et les propriétés du café et du chocolat tout en minimisant les émissions de carbone et en améliorant la résilience alimentaire.
GEA aide ses clients à tester des produits et des ingrédients alternatifs aux œufs, obtenus par fermentation de précision, et à gérer le passage à l’échelle industrielle.